Ciclosporin: Mechanism, Research Settings and What Studies Report

What Ciclosporin Is

Ciclosporin (also written cyclosporine or cyclosporin A) is a cyclic undecapeptide — an eleven-residue ring that contains several N-methylated and non-proteinogenic amino acids — originally isolated from a soil fungus. Its heavy N-methylation and cyclic backbone make it resistant to the peptidases that rapidly degrade most linear peptides, and they give the molecule enough lipophilicity to cross cell membranes and reach an intracellular target. That combination of features is why ciclosporin is frequently used as a teaching example in peptide pharmacology: it demonstrates that a peptide-derived molecule can behave, in absorption and distribution terms, more like a conventional oral drug than like an injectable peptide hormone.

Ciclosporin is a licensed prescription immunosuppressant in many jurisdictions, with approved formulations used in organ transplantation and in selected inflammatory conditions. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision or medication. Nothing here describes a regimen, and no quantities are stated beyond what the cited papers themselves report.

Mechanism: Cyclophilin, Calcineurin and NFAT

Inside the cell, ciclosporin binds the immunophilin cyclophilin. The resulting drug–protein complex inhibits calcineurin, the calcium- and calmodulin-dependent phosphatase that dephosphorylates nuclear factor of activated T cells (NFAT). With calcineurin inhibited, NFAT remains phosphorylated in the cytoplasm rather than translocating to the nucleus, and transcription of interleukin-2 and related cytokine genes falls. The downstream consequence is reduced clonal expansion of activated T lymphocytes — the core of ciclosporin's immunosuppressive profile.

NFAT signalling beyond T cells

NFAT family transcription factors are not confined to lymphocytes, and research has explored ciclosporin as a tool for interrogating that biology. A 2025 preclinical haematology study reported that ciclosporin A potentiated venetoclax efficacy in FLT3-ITD acute myeloid leukaemia by targeting an NFATC1–AKT–mTOR–BCL-2/MCL-1 signalling axis (PMID 40328636). That work was laboratory and model-based rather than a treatment recommendation, but it illustrates how the calcineurin–NFAT axis intersects with apoptosis regulation in non-immune contexts.

Human Clinical Settings Described in the Literature

Atopic dermatitis

Severe atopic dermatitis is one of the best-documented non-transplant settings. A survey study examined dermatologist attitudes toward ciclosporin use in atopic dermatitis, mapping how specialists viewed the agent relative to other systemic options (PMID 31996056). A separate cohort analysis reported outcomes of prolonged and low-dose ciclosporin in an Asian population, addressing the question of what happens when treatment extends beyond short courses (PMID 31469020).

In paediatric populations, researchers conducted a secondary analysis of the TREatment of severe Atopic dermatitis Trial (TREAT) that examined the exposure–response relationship of ciclosporin and methotrexate in children and young people with severe atopic dermatitis (PMID 40168525). Exposure–response analyses of this kind ask whether measured drug exposure, rather than the nominal amount administered, tracks with clinical change — a methodological point that recurs across immunosuppressant research.

Behçet's disease and uveitis

A randomised, open-label, head-to-head trial compared combinations of immunomodulatory agents for the prevention of uveitis relapse in patients with severe Behçet's disease who were already receiving corticosteroid therapy (PMID 39236720). Head-to-head designs in this field are uncommon, which is why the study drew attention among rheumatology and ophthalmology readers.

Dermatological case literature

Ciclosporin also appears across the neutrophilic dermatosis case literature. A clinical and experimental dermatology report described periungual lesions in pyoderma gangrenosum, documenting an uncommon anatomical presentation of that condition (PMID 19438552).

Transplantation and conditioning protocols

In haematopoietic stem cell transplantation, ciclosporin has historically been a component of graft-versus-host disease prophylaxis, and part of the current research question is whether it can be omitted. Researchers reported outcomes of an optimised ciclosporin-free haploidentical HSCT protocol in paediatric patients with cerebral adrenoleukodystrophy (PMID 42152527).

Veterinary Literature

Veterinary dermatology has generated a substantial ciclosporin evidence base, partly because licensed veterinary formulations exist. A systematic review of treatment of the feline atopic syndrome assessed the published evidence for systemic and topical interventions used in cats (PMID 33470011). In dogs, a clinical guideline paper set out recommendations for the use of antipruritic drugs in the control of the most frequent pruritic skin diseases (PMID 35448647).

One mechanistic veterinary question concerns whether immunosuppression alters the skin's microbial ecology. A controlled study reported that glucocorticosteroids and ciclosporin did not significantly impact canine cutaneous microbiota (PMID 29471815).

Pharmacokinetics and Drug Interactions

Ciclosporin is a substrate and inhibitor of cytochrome P450 3A4 and of P-glycoprotein, which places it at the centre of a large interaction literature. It also inhibits organic anion transporting polypeptides involved in hepatic uptake of statins and other drugs. Researchers reviewing the metabolism, pharmacokinetics and drug interactions of ezetimibe catalogued how co-administered agents alter exposure to lipid-lowering therapy, a body of work directly relevant to transplant recipients receiving immunosuppression (PMID 15871634).

Adverse Events: What Studies Report

The most concrete interaction signal in the verified literature comes from a case report describing ciclosporin–simvastatin co-induced rhabdomyolysis, in which the authors documented muscle breakdown attributed to the combination of the two agents (PMID 31772127). Case reports describe single patients and cannot establish frequency, but they are how transporter-mediated statin interactions are typically first flagged.

Duration of therapy is a recurring safety theme. The cohort study of prolonged and low-dose ciclosporin was designed specifically to describe what happened over extended treatment in an Asian population (PMID 31469020), and the survey of dermatologist attitudes captured how clinicians weighed ciclosporin against alternatives in atopic dermatitis practice (PMID 31996056). In transplantation, the development of an optimised ciclosporin-free haploidentical protocol reflected the same underlying motivation to test whether the agent can be removed from a regimen (PMID 42152527). On the microbiome side, the canine study reported no significant impact of ciclosporin or glucocorticosteroids on cutaneous microbiota (PMID 29471815).

Limitations of the Evidence

• Several of the strongest ciclosporin datasets come from veterinary dermatology, and species differences in metabolism limit extrapolation (PMID 33470011).
• Preclinical oncology findings describe model systems, not clinical outcomes (PMID 40328636).
• Exposure–response analyses are secondary analyses of trial data and are hypothesis-generating (PMID 40168525).
• Survey and case-report designs capture practice patterns and individual events rather than comparative efficacy (PMID 31996056).

References

• Ciclosporin A potentiates venetoclax efficacy in FLT3-ITD AML by targeting the NFATC1-AKT-mTOR-BCL-2/MCL-1 signaling axis (British Journal of Haematology, 2025)
• Exposure-response of ciclosporin and methotrexate in children and young people with severe atopic dermatitis: a secondary analysis of the TREAT trial (Clinical and Experimental Dermatology, 2025)
• Outcomes of prolonged and low-dose ciclosporin in an Asian population (Journal of Dermatological Treatment, 2021)
• Dermatologist attitudes toward ciclosporin use in atopic dermatitis (Journal of Dermatological Treatment, 2021)
• Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet's disease already on corticosteroid therapy (The Lancet Rheumatology, 2024)
• Outcomes of an optimized ciclosporin-free haploidentical HSCT protocol in paediatric patients with cerebral adrenoleukodystrophy (British Journal of Haematology, 2026)
• Double trouble: ciclosporin-simvastatin coinduced rhabdomyolysis (BMJ Case Reports, 2019)
• Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions (Clinical Pharmacokinetics, 2005)
• Treatment of the feline atopic syndrome - a systematic review (Veterinary Dermatology, 2021)
• Clinical Guidelines for the Use of Antipruritic Drugs in the Control of the Most Frequent Pruritic Skin Diseases in Dogs (Veterinary Sciences, 2022)
• Glucocorticosteroids and ciclosporin do not significantly impact canine cutaneous microbiota (BMC Veterinary Research, 2018)
• Periungual lesions in pyoderma gangrenosum (Clinical and Experimental Dermatology, 2009)